Pandemic pharmaceutical dosing effects on wastewater treatment: no adaptation of activated sludge bacteria to degrade the antiviral drug Oseltamivir (Tamiflu (R)) and loss of nutrient removal performance

ResearchSpace/Manakin Repository

Show simple item record

dc.contributor.author Slater, FR en
dc.contributor.author Singer, AC en
dc.contributor.author Turner, Susan en
dc.contributor.author Barr, JJ en
dc.contributor.author Bond, PL en
dc.date.accessioned 2011-09-13T20:24:53Z en
dc.date.issued 2011-02 en
dc.identifier.citation FEMS Microbiology Letters 315(1):17-22 Feb 2011 en
dc.identifier.issn 0378-1097 en
dc.identifier.uri http://hdl.handle.net/2292/7915 en
dc.description.abstract The 2009–2010 influenza pandemic saw many people treated with antivirals and antibiotics. High proportions of both classes of drugs are excreted and enter wastewater treatment plants (WWTPs) in biologically active forms. To date, there has been no study into the potential for influenza pandemic-scale pharmaceutical use to disrupt WWTP function. Furthermore, there is currently little indication as to whether WWTP microbial consortia can degrade antiviral neuraminidase inhibitors when exposed to pandemic-scale doses. In this study, we exposed an aerobic granular sludge sequencing batch reactor, operated for enhanced biological phosphorus removal (EBPR), to a simulated influenza-pandemic dosing of antibiotics and antivirals for 8 weeks. We monitored the removal of the active form of Tamiflu®, oseltamivir carboxylate (OC), bacterial community structure, granule structure and changes in EBPR and nitrification performance. There was little removal of OC by sludge and no evidence that the activated sludge community adapted to degrade OC. There was evidence of changes to the bacterial community structure and disruption to EBPR and nitrification during and after high-OC dosing. This work highlights the potential for the antiviral contamination of receiving waters and indicates the risk of destabilizing WWTP microbial consortia as a result of high concentrations of bioactive pharmaceuticals during an influenza pandemic. en
dc.language EN en
dc.publisher WILEY-BLACKWELL PUBLISHING, INC en
dc.relation.ispartofseries FEMS MICROBIOL LETT en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0378-1097/ en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.subject antiviral degradation en
dc.subject pharmaceutical ecotoxicity en
dc.subject enhanced biological phosphorus removal (EBPR) en
dc.subject BIOLOGICAL PHOSPHORUS REMOVAL en
dc.subject ENVIRONMENTAL FATE en
dc.subject SYSTEMS en
dc.subject SCALE en
dc.subject ACCUMULIBACTER en
dc.subject NEURAMINIDASE en
dc.subject CARBOXYLATE en
dc.subject ORGANISMS en
dc.subject COMMUNITY en
dc.subject RISKS en
dc.title Pandemic pharmaceutical dosing effects on wastewater treatment: no adaptation of activated sludge bacteria to degrade the antiviral drug Oseltamivir (Tamiflu (R)) and loss of nutrient removal performance en
dc.type Journal Article en
dc.identifier.doi 10.1111/j.1574-6968.2010.02163.x en
pubs.issue 1 en
pubs.begin-page 17 en
pubs.volume 315 en
dc.rights.holder Copyright: 2010 Federation of European Microbiological Societies. en
dc.identifier.pmid 21133989 en
pubs.end-page 22 en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Article en
pubs.elements-id 223094 en
pubs.record-created-at-source-date 2011-10-25 en
pubs.dimensions-id 21133989 en


Full text options

Full text for this item is not available in ResearchSpace.

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Advanced Search

Browse